Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) announced management participation in three investor conferences in October 2025. CTXR management will attend LD Micro Main Event XIX (Oct 19-21, 2025) in San Diego and the Think Equity Conference (Oct 30, 2025) in New York. CTOR management will attend the 2025 Maxim Growth Summit (Oct 22-23, 2025) in New York.
Both companies said investors may request 1-on-1 meetings via the event platforms or by contacting the companies' investor relations teams; CTOR noted scheduled meetings with institutional investors and Maxim senior analysts.
Citius Pharmaceuticals (Nasdaq: CTXR) e Citius Oncology (Nasdaq: CTOR) hanno annunciato la partecipazione dello management a tre conferenze per investitori nell'ottobre 2025. Il management di CTXR parteciperà al LD Micro Main Event XIX (19-21 ottobre 2025) a San Diego e al Think Equity Conference (30 ottobre 2025) a New York. Il management di CTOR parteciperà al 2025 Maxim Growth Summit (22-23 ottobre 2025) a New York.
Entrambe le aziende hanno detto che gli investitori possono richiedere incontri one-on-one tramite le piattaforme degli eventi o contattando i rispettivi uffici investitori; CTOR ha fatto presente incontri programmati con investitori istituzionali e analisti senior di Maxim.
Citius Pharmaceuticals (Nasdaq: CTXR) y Citius Oncology (Nasdaq: CTOR) anunciaron la participación de la gerencia en tres conferencias para inversionistas en octubre de 2025. La gerencia de CTXR asistirá al LD Micro Main Event XIX (del 19 al 21 de octubre de 2025) en San Diego y a la Think Equity Conference (30 de octubre de 2025) en Nueva York. La gerencia de CTOR asistirá al 2025 Maxim Growth Summit (del 22 al 23 de octubre de 2025) en Nueva York.
Ambas compañías dijeron que los inversionistas pueden solicitar reuniones 1-a-1 a través de las plataformas del evento o contactando a los equipos relaciones con inversores de cada empresa; CTOR señaló reuniones programadas con inversionistas institucionales y analistas senior de Maxim.
Citius Pharmaceuticals (나스닥: CTXR) 및 Citius Oncology (나스닥: CTOR)는 2025년 10월 세 차례의 투자자 컨퍼런스에 경영진이 참여한다고 발표했습니다. CTXR 경영진은 샌디에이고에서 열리는 LD Micro Main Event XIX (2025년 10월 19-21일)와 뉴욕에서 열리는 Think Equity Conference (2025년 10월 30일)에 참석합니다. CTOR 경영진은 뉴욕에서 열리는 2025 Maxim Growth Summit (2025년 10월 22-23일)에 참석합니다.
두 회사는 투자자들이 이벤트 플랫폼을 통해 또는 각 기업의 IR팀에 연락해 1대1 미팅을 요청할 수 있다고 밝혔으며, CTOR는 기관 투자자와 Maxim의 수석 애널리스트와의 일정 회의를 언급했습니다.
Citius Pharmaceuticals (Nasdaq: CTXR) et Citius Oncology (Nasdaq: CTOR) ont annoncé la participation de leur direction à trois conférences pour investisseurs en octobre 2025. La direction de CTXR assistera au LD Micro Main Event XIX (19–21 octobre 2025) à San Diego et à la Think Equity Conference (30 octobre 2025) à New York. La direction de CTOR assistera au 2025 Maxim Growth Summit (22–23 octobre 2025) à New York.
Les deux entreprises ont indiqué que les investisseurs peuvent demander des réunions en tête-à-tête via les plateformes des événements ou en contactant les équipes relations investisseurs des sociétés; CTOR a mentionné des réunions prévues avec des investisseurs institutionnels et des analystes principaux de Maxim.
Citius Pharmaceuticals (Nasdaq: CTXR) und Citius Oncology (Nasdaq: CTOR) gaben bekannt, dass das Management an drei Investorenkonferenzen im Oktober 2025 teilnehmen wird. Das CTXR-Management wird am LD Micro Main Event XIX (19.–21. Oktober 2025) in San Diego und an der Think Equity Conference (30. Oktober 2025) in New York teilnehmen. Das CTOR-Management wird am 2025 Maxim Growth Summit (22.–23. Oktober 2025) in New York teilnehmen.
Beide Unternehmen sagten, dass Investoren 1-zu-1- Meetings über die Event-Plattformen oder durch Kontaktaufnahme mit den Investor-Relations-Teams der Unternehmen anfordern können; CTOR merkte an, dass es geplante Meetings mit institutionellen Investoren und den Senior-Analysten von Maxim gibt.
Citius Pharmaceuticals (ناسداك: CTXR) وCitius Oncology (ناسداك: CTOR) أعلنوا عن مشاركة الإدارة في ثلاث مؤتمرات للمستثمرين في أكتوبر 2025. سيشارك إدارة CTXR في LD Micro Main Event XIX (19-21 أكتوبر 2025) في سان دييغو وفي Think Equity Conference (30 أكتوبر 2025) في نيويورك. سيشارك إدارة CTOR في 2025 Maxim Growth Summit (22-23 أكتوبر 2025) في نيويورك.
قالت الشركتان إن المستثمرين يمكنهم طلب اجتماعات فردية عبر منصات الحدث أو من خلال التواصل مع فرق العلاقات مع المستثمرين في كل شركة؛ أشارت CTOR إلى وجود اجتماعات مجدولة مع مستثمرين مؤسسيين وكبار محللي Maxim.
Citius Pharmaceuticals (纳斯达克：CTXR) 与 Citius Oncology (纳斯达克：CTOR) 宣布管理层将参加在2025年10月举行的三场投资者大会。CTXR 管理层将出席在圣地亚哥举行的 LD Micro Main Event XIX (2025年10月19-21日) 以及在纽约举行的 Think Equity Conference (2025年10月30日)。CTOR 管理层将出席在纽约举行的 2025 Maxim Growth Summit (2025年10月22-23日)。
两家公司表示，投资者可通过活动平台或联系各自的投资者关系团队请求一对一会面；CTOR 指出与机构投资者及 Maxim 的高级分析师之间已安排会议。
- None.
- None.
LD Micro Main Event XIX, October 19-21, 2025
2025 Maxim Growth Summit, October 22-23, 2025
The Think Equity Conference, October 30, 2025
Citius Pharmaceuticals (Nasdaq: CTXR)
|
Event: |
LD Micro Main Event XIX |
|
Date: |
October 19-21, 2025 |
|
Location: |
Hotel Del Coronado, |
|
Event website: |
|
|
|
|
|
|
|
|
Event: |
Think Equity Conference |
|
Date: |
October 30, 2025 |
|
Location: |
Mandarin Oriental, |
|
Event website: |
|
Interested parties may schedule 1-on-1 meetings with Citius management by registering through the event platform or contacting the Company's investor relations team.
Citius Oncology (Nasdaq: CTOR)
|
Event: |
2025 Maxim Growth Summit |
|
Date: |
October 22-23, 2025 |
|
Location: |
The Hard Rock Hotel, |
|
Event website: |
Citius Oncology will be meeting with institutional investors in a one-on-one format, and senior Maxim analysts during the event.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns
About Citius Oncology, Inc.
Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-and-citius-oncology-to-participate-in-upcoming-october-2025-conferences-302586084.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
When will Citius Pharmaceuticals (CTXR) present at LD Micro Main Event XIX?
What date will Citius Pharmaceuticals (CTXR) attend the Think Equity Conference?
When and where will Citius Oncology (CTOR) participate in the Maxim Growth Summit?
How can investors schedule 1-on-1 meetings with CTXR or CTOR at the October 2025 conferences?
Will Citius Oncology (CTOR) meet with analysts at the Maxim Growth Summit?
Which Nasdaq ticker symbols correspond to the companies attending the October 2025 conferences?
